Sat.May 27, 2023 - Fri.Jun 02, 2023

article thumbnail

Big Pharma inventory management trends revealed

European Pharmaceutical Review

The inventory position of 28 major pharmaceutical manufacturers in 2022 has been revealed in an annual report. Analysis explored the impact of macro-trends on inventory management from corporate reports of Big Pharma companies including Merck, AstraZeneca and Pfizer. It investigated how excessive inventories are affecting the industry and what factors could influence inventory growth in 2023.

article thumbnail

STAT+: Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts

STAT

In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira — one of the world’s best-selling medicines — at a steep discount, and will work with Mark Cuban’s generic drug company to make the medicine available directly to consumers for even less. Specifically, the Coherus medicine will carry a $995 list price for a carton of two autoinjectors, an 85% discount from the $6,922 that AbbVie charges for Humira, which is used to treat rheumatoid arthri

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Phenobarbital as First-Line Medication for Alcohol Withdrawal: Have You Switched From Benzodiazepines Yet?

ALiEM - Pharm Pearls

Are you using phenobarbital instead of benzodiazepines as the first-line monotherapy for patients in alcohol withdrawal in the Emergency Department (ED)? If not, you probably should be. Another old drug for a new indication, right? Well not exactly. Phenobarbital is indeed an older and relatively cheap drug (less than $20 per loading dose) that has gained some press recently for the treatment of acute alcohol withdrawal [1-3].

Inpatient 246
article thumbnail

Woman of the Week: Mirati Therapeutics’ Laurie Stelzer

PharmaVoice

With the recent approval of Krazati, the biotech veteran is guiding Mirati into its next phase as a commercial-based organization.

245
245
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Biohaven sends latest drug to FDA, despite past trial setback

BioPharma Dive

The biotech, best known for its success developing migraine medicines, will seek approval of a treatment that failed a Phase 3 trial but showed signs of a positive effect.

126
126
article thumbnail

Studies show top surgery is safe for fat patients, but some surgeons still mandate weight loss

STAT

Vince Wescott was ready for top surgery. He had the cash saved up, he’d gotten a letter from his therapist, and he’d sent in the required photos of his chest and torso in preparation for a consultation. When his surgeon’s office called unexpectedly, he picked up, assuming that they were missing paperwork or needed to reschedule.

261
261

More Trending

article thumbnail

A key to ‘winning’ in today’s market — and other trends pharma leaders are tracking

PharmaVoice

Healthcare pros share the market drivers they believe are having the biggest impact on the industry.

246
246
article thumbnail

ICYMI: PBM exec admits choosing profits over patients

PhRMA

With Congress discussing policy changes that would lower drug costs for patients and rein in powerful middlemen, insurers and their PBMs are dusting off their old playbook and once again threatening to increase costs for employers if required to do their job and actually provide meaningful coverage to patients. But recent remarks by one executive make clear that the PBM industry has a choice: protect its profits or lower costs for patients.

122
122
article thumbnail

STAT+: Tempus launches an AI ‘assistant’ for thousands of oncologists

STAT

Tempus, a company that combines DNA sequencing for cancer with artificial intelligence, said Thursday that it is launching a voice-and-text assistant called Tempus One that will give physicians much easier access to patient data. The AI assistant is being launched ahead of the annual meeting of the American Society of Clinical Oncology in Chicago. Eric Lefkofsky, Tempus’ founder and CEO, told STAT Tempus will be rolling the product, called Tempus One, out to the 6,000 doctors that prescri

283
283
article thumbnail

Coherus sets steep discount for Humira copycat, plans direct sales

BioPharma Dive

The biotech will price its biosimilar Yusimry at 85% below Humira’s list price when it launches next month, and charge even less if bought through Mark Cuban’s pharmacy.

article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

CVS is exiting clinical trials. Does this spell trouble for retail-based research?

PharmaVoice

Walgreens leaders are not deterred and hope to fill the holes left behind by the pharmacy giant.

148
148
article thumbnail

SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine

Pharmaceutical Technology

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. SKYCovion is intended for the prevention of Covid-19 resulting from SARS-CoV-2 infection in individuals aged 18 years and above. The authorisation allows the distribution of the vaccine in Scotland, Wales and England.

Vaccines 119
article thumbnail

Opinion: PAs need a new name, but ‘physician associate’ won’t cut it. Here’s a better idea

STAT

I’m standing over an operating table, excising a skin cancer from the forehead of an elderly gentleman while soft piano music echoes off the floor tiles. I’ve performed this procedure thousands of times, and I always enjoy the placid focus and deep satisfaction performing cutaneous surgery brings me. All I’ve done in adulthood has brought me here: cadaver prosections in anatomy labs,  mentorship from dermatologic surgeons , and mastering various  knot-tying techniq

251
251
article thumbnail

Amylyx’s ALS drug could face rejection in Europe

BioPharma Dive

The biotech said a committee advising the European Medicines Agency is “trending” toward issuing a negative opinion of its drug Relyvrio, which was approved in the U.S. last year.

119
119
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

FDA approves ANDA of 20mg generic Nitisinone capsules

Pharma Times

Nitisinone capsules are indicated for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine

113
113
article thumbnail

XtalPi announces $250m AI drug discovery collaboration with Eli Lilly

Pharmaceutical Technology

XtalPi has made a partnership deal with US-based Eli Lilly to leverage artificial intelligence (AI) for drug discovery. XtalPi will receive $250m in upfront and milestone payments. The two companies will use XtalPi’s integrated AI capabilities and robotics platform for the de novo [without consideration of previous instances] design and delivery of drug candidates for an undisclosed target.

article thumbnail

‘A target on my back’: New survey shows racism is a huge problem in nursing

STAT

A family nurse practitioner in New York City, Jose M. Maria has come to expect overt racism from patients. “I’ve been called the N-word, I’ve been called, you name it,” he said. A triple minority in nursing — Black, Latino, and male — he often gets mistaken for a janitor. More subtle racist behavior has come from supervisors and fellow nurses in past jobs, too — uncomfortable looks in the break room, extra questioning from supervisors over narcoti

251
251
article thumbnail

Novartis drug helps stop breast cancer’s return in large study

BioPharma Dive

Treatment with Kisqali reduced the risk of disease recurrence when used after surgery, potentially positioning Novartis to win a similar adjuvant approval as Lilly’s rival therapy Verzenio.

117
117
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

Pharma Times

The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15 - News - PharmaTimes

112
112
article thumbnail

US companies drive 2023 drug launches positioned for blockbuster success by 2028

Pharmaceutical Technology

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut.

Vaccines 105
article thumbnail

Opinion: The DEA needs to officially allow telehealth prescribing for opioid use disorder

STAT

The statistics are dismal, though they bear repeating: 81% of overdose deaths in the U.S. in 2021 involved an opioid. But as an addiction medicine specialist, there are figures that give me hope: one seminal study showed that 75% of patients who were given the FDA-approved medication buprenorphine to treat opioid use disorder daily for 12 months remained in recovery — compared with 0% who did not receive buprenorphine treatment for the entire 12 months.

251
251
article thumbnail

Pfizer says hemophilia drug succeeded in Phase 3 study

BioPharma Dive

The drug, called marstacimab, outperformed factor treatment in the study, and wasn’t associated with the kind of safety signals that have dogged other medicines in its class.

107
107
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

New UK drug delivery centre to support RNA therapeutic development

European Pharmaceutical Review

The Centre for Process Innovation (CPI) is set to establish a new UK Intracellular Drug Delivery Centre to develop new lipid nanoparticle (LNP) formulations for RNA medicine delivery, and a framework to advance next-generation nano delivery systems. Under the first-of-its-kind partnership in the UK, CPI will work with the Medicines Discovery Catapult, the University of Strathclyde, the University of Liverpool and Imperial College London using a £10 million, three-year grant funded by Innovate UK

article thumbnail

My Takeaways From The book Fish!

The Honest Apothecary

As a pharmacist in a management and leadership role, I’m always looking for books with ideas about how to lead better. l love books about creating a better working environment, and anything that may uncover some blindspots I may have about my own organization. When I stumbled across the book Fish! in a thrift store for a mere $2.00 it caught my eye.

article thumbnail

Hospitals want to buy doctors’ happiness with Nuance’s AI scribe. What they’re paying varies

STAT

Microsoft-owned Nuance Communications sells its AI medical scribe platform to health care providers on a simple promise: If they shell out big bucks for the high-tech product, they can decrease doctor burnout and ultimately make more money by enabling doctors to see more patients. But executives at four health systems using the software, called DAX, told STAT that while the software might make it possible to see more patients, or justify higher charges to insurers for visits, the high price tag

Hospitals 246
article thumbnail

FDA pauses PepGen’s plans to test muscle disease drug

BioPharma Dive

The company’s experimental treatment for myotonic dystrophy became the latest neuromuscular disease therapy to face a regulatory roadblock before the start of human testing.

103
103
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Lonza to acquire Synaffix to strengthen ADC development

Pharma Times

Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services - News - PharmaTimes

113
113
article thumbnail

Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics

PhRMA

As we recognize Mental Health Awareness Month, I had the opportunity to connect with PhRMA board member Barry Greene, CEO of Sage Therapeutics, about the company’s efforts to address mental health.

103
103
article thumbnail

Opinion: More young people should be getting their cholesterol tested and taking statins

STAT

For busy primary care physicians like me, an annual physical with a 27-year-old male is a blessing. Since we’re always running late, a quick visit with a young healthy adult offers the rare chance to get back on schedule. But I didn’t give my own doctor that chance to get back on schedule when I went to see him for my physical a few months ago.

251
251
article thumbnail

Pfizer’s RSV vaccine wins FDA approval in older adults

BioPharma Dive

The shot’s clearance comes several weeks after the regulator made GSK’s Arexvy the first vaccine for RSV in the U.S.

Vaccines 124
article thumbnail

EC approves Briumvi to treat relapsing forms of multiple sclerosis

Pharmaceutical Technology

The European Commission (EC) has approved TG Therapeutics’ Briumvi (ublituximab-xiiy) to treat relapsing forms of multiple sclerosis (RMS) in adult patients. Briumvi is an anti-CD20 monoclonal antibody indicated for RMS adult patients with active disease which is defined by clinical or imaging features. It has been engineered to remove certain sugar molecules generally expressed on the antibody.

98